HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors.

Published in: Breast cancer research : BCR (2018)

These discoveries reveal therapeutic opportunities for combining anti-HER2 therapy with anti-androgen agents in breast cancer, and highlight the potential for broader therapeutic use of HER2 inhibitors.

Keyphrases

papillary thyroid
squamous cell
childhood cancer
lymph node metastasis
gene expression
squamous cell carcinoma
stem cells
genome wide
young adults
climate change
mesenchymal stem cells
bone marrow
human health
replacement therapy
breast cancer risk